Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 4066
1. Reid F, Choi J, Williams M, Chan S: Prospective evaluation of the Sunshine Appendicitis Grading System score. ANZ J Surg; 2017 May;87(5):368-371
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of the Sunshine Appendicitis Grading System score.
  • BACKGROUND: Although there is a wealth of information predicting risk of post-operative intra-abdominal collection and guiding antibiotic therapy following appendicectomy, confusion remains because of lack of consensus on the clinical severity and definition of 'complicated' appendicitis.
  • This study aimed to develop a standardized intra-operative grading system: Sunshine Appendicitis Grading System (SAGS) for acute appendicitis that correlates independently with the risk of intra-abdominal collections.
  • METHODS: Two-hundred and forty-six patients undergoing emergency laparoscopy for suspected appendicitis were prospectively scored according to the severity of appendicitis and followed up for complications including intra-abdominal collection.
  • After termination of the study, the SAGS score was repeated by an independent surgeon based on operation notes and intra-operative photography to determine inter-rater agreement.
  • The primary outcome measure was incidence of intra-abdominal collection, secondary outcome measures were all complications and length of stay.
  • RESULTS: SAGS score demonstrated good inter-rater agreement (kappa K<sub>w</sub> 0.869; 95% CI 0.796-0.941; P < 0.001).
  • A risk ratio of 2.594 (95% CI 0.655-4.065; P < 0.001) for intra-abdominal collection was found using SAGS score as a predictor.
  • The discriminative ability of SAGS score was supported by an area under the curve value of 0.850 (95% CI 0.799-0.892; P < 0.001).
  • CONCLUSIONS: SAGS score can be used to simply and accurately classify the severity of appendicitis and to independently predict the risk of intra-abdominal collection.
  • It can therefore be used to stratify risk, guide antibiotic therapy, follow-up and standardize the definitions of appendicitis severity for future research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2015 Royal Australasian College of Surgeons.
  • (PMID = 26333132.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; appendicitis / intra-abdominal infection / laparoscopy / risk / severity of illness index
  •  go-up   go-down


2. Hong SM, Choi J, Ryu K, Ro JY, Yu E: Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. Arch Pathol Lab Med; 2006 Jan;130(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas.
  • CONTEXT: The p16 gene is one of the tumor suppressor genes, and its inactivation results in abnormal regulation of the cell cycle in human neoplasms.
  • Promoter hypermethylation, a mechanism of p16 gene inactivation, has been reported to play an important role in tumorigenesis and to be related to patient prognosis in several carcinomas.
  • OBJECTIVE: To determine the role of the p16 gene in extrahepatic bile duct (EBD) carcinomas.
  • DESIGN: We examined promoter hypermethylation of the p16 gene using a methylation-specific polymerase chain reaction and the expression of the p16 protein using an immunohistochemical staining method in 90 cases of EBD carcinomas.
  • We then compared the data with various clinicopathologic parameters, including survival rate.
  • RESULTS: Promoter hypermethylation was observed in 69 (77%) of the 90 cases.
  • Of 69 hypermethylated cases, 32 (46%) demonstrated loss of p16 expression.
  • Promoter hypermethylation of the p16 gene was more commonly observed in tumors with vascular invasion (22 [92%] of 24 cases) than without vascular invasion (71%, P = .03).
  • Furthermore, p16 promoter hypermethylation with loss of p16 expression was more frequently observed in cases with lymph node metastasis (P = .006) and higher tumor stage group (P = .04).
  • However, there was no significant difference in survival rate according to the status of p16 promoter methylation and/or p16 expression.
  • CONCLUSION: Promoter hypermethylation is an important mechanism in the inactivation of the p16 gene in EBD carcinogenesis.
  • Furthermore, the loss of p16 expression, with or without p16 gene promoter hypermethylation, is closely related to the tumor progression in EBD carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Bile Duct Neoplasms / genetics. Bile Ducts, Extrahepatic. DNA Methylation. Gene Silencing. Genes, p16. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Neoplasm / analysis. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microdissection. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390235.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm
  •  go-up   go-down


3. Choi J, Jiang X, Jeong JB, Lee SH: Anticancer activity of protocatechualdehyde in human breast cancer cells. J Med Food; 2014 Aug;17(8):842-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of protocatechualdehyde in human breast cancer cells.
  • Protocatechualdehyde (PCA) is a natural polyphenol compound isolated from the root of the herb S. miltiorrhiza and barley tea plants.
  • PCA possesses antiproliferative and pro-apoptotic properties in human colorectal cancer cells.
  • However, the cellular mechanism has not been fully understood.
  • β-catenin and cyclin D1 are proto-oncogene that is overexpressed in many types of cancers and leads to cancer development.
  • The present study was performed to elucidate the molecular mechanism by which PCA stimulates cell growth arrest and apoptosis in human breast cancer cells.
  • PCA repressed cell proliferation and induced apoptosis in dose-dependent manner.
  • PCA suppressed the expression of β-catenin and cyclin D1 with no changes in mRNA levels.
  • Inhibition of proteosomal degradation using MG-132 and Ada-(Ahx)3-(Leu)3-vinyl sulfone ameliorates PCA-induced downregulation of β-catenin and cyclin D1.
  • PCA treatment decreased the half-life of β-catenin and cyclin D1.
  • PCA-mediated β-catenin downregulation depends on GSK3β.
  • We further provide the evidence that PCA increased nuclear translocation of nuclear factor kappa-B (NF-κB) and the blockage of NF-κB using Bay11-7082 inhibited PCA-mediated β-catenin downregulation.
  • The current study demonstrates that PCA suppress β-catenin expression through GSK3β- and NF-κB-mediated proteosomal degradation.
  • In addition, PCA decreased cyclin D1 expression independent to β-catenin through proteosomal degradation.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzaldehydes / pharmacology. Breast Neoplasms / drug therapy. Catechols / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cyclin D1 / genetics. Cyclin D1 / metabolism. Down-Regulation / drug effects. Female. Glycogen Synthase Kinase 3 / genetics. Glycogen Synthase Kinase 3 / metabolism. Humans. NF-kappa B / genetics. NF-kappa B / metabolism. beta Catenin / genetics. beta Catenin / metabolism


Advertisement
4. Choi J, Choi KH, Felice Reddy L, Fiszdon JM: Measuring motivation in schizophrenia: is a general state of motivation necessary for task-specific motivation? Schizophr Res; 2014 Mar;153(1-3):209-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring motivation in schizophrenia: is a general state of motivation necessary for task-specific motivation?
  • Despite the important role of motivation in rehabilitation and functional outcomes in schizophrenia, to date, there has been little emphasis on how motivation is assessed.
  • This is important, since different measures may tap potentially discrete motivational constructs, which in turn may have very different associations to important outcomes.
  • In the current study, we used baseline data from 71 schizophrenia spectrum outpatients enrolled in a rehabilitation program to examine the relationship between task-specific motivation, as measured by the Intrinsic Motivation Inventory (IMI), and a more general state of volition/initiation, as measured by the three item Quality of Life (QLS) motivation index.
  • We also examined the relationship of these motivation measures to demographic, clinical and functional variables relevant to rehabilitation outcomes.
  • The two motivation measures were not correlated, and participants with low general state motivation exhibited a full range of task-specific motivation.
  • Only the QLS motivation index correlated with variables relevant to rehabilitation outcomes.
  • The lack of associations between QLS motivation index and IMI subscales suggests that constructs tapped by these measures may be divergent in schizophrenia, and specifically that task-specific intrinsic motivation is not contingent on a general state of motivation.
  • That is, even in individuals with a general low motivational state (i.e. amotivation), interventions aimed at increasing task-specific motivation may still be effective.
  • Moreover, the pattern of interrelationships between the QLS motivation index and variables relevant to psychosocial rehabilitation supports its use in treatment outcome studies.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier B.V. All rights reserved.
  • [Cites] Psychiatry Res. 2013 Nov 30;210(1):43-9 [23796827.001]
  • [Cites] J Nerv Ment Dis. 2013 Mar;201(3):173-8 [23417014.001]
  • [Cites] Schizophr Bull. 1984;10(3):388-98 [6474101.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] Res Q Exerc Sport. 1989 Mar;60(1):48-58 [2489825.001]
  • [Cites] J Pers. 1994 Mar;62(1):119-42 [8169757.001]
  • [Cites] Psychiatry Res. 1994 Jun;52(3):295-303 [7991723.001]
  • [Cites] Res Q Exerc Sport. 1997 Mar;68(1):20-32 [9094760.001]
  • [Cites] Schizophr Bull. 2005 Oct;31(4):875-81 [16079388.001]
  • [Cites] Schizophr Bull. 2006 Jul;32(3):474-85 [16641424.001]
  • [Cites] Schizophr Bull. 2000;26(3):631-58 [10993403.001]
  • [Cites] Schizophr Res. 2001 Mar 30;48(2-3):351-60 [11295387.001]
  • [Cites] Schizophr Bull. 2001;27(2):235-45 [11354591.001]
  • [Cites] Am Psychol. 2000 Jan;55(1):68-78 [11392867.001]
  • [Cites] Psychiatry Res. 2013 Jun 30;208(1):78-80 [23566367.001]
  • [Cites] J Psychiatr Res. 2007 Dec;41(12):1012-8 [17014866.001]
  • [Cites] Biol Psychiatry. 2008 Mar 1;63(5):505-11 [17662256.001]
  • [Cites] Schizophr Res. 2008 Oct;105(1-3):95-104 [18715756.001]
  • [Cites] Schizophr Res. 2009 Nov;115(1):74-81 [19783407.001]
  • [Cites] J Nerv Ment Dis. 2010 Jan;198(1):28-34 [20061866.001]
  • [Cites] Schizophr Res. 2010 May;118(1-3):12-9 [19716270.001]
  • [Cites] Schizophr Bull. 2010 Sep;36(5):935-48 [20462998.001]
  • [Cites] Schizophr Bull. 2010 Sep;36(5):957-65 [20634277.001]
  • [Cites] J Nerv Ment Dis. 2011 Sep;199(9):672-7 [21878781.001]
  • [Cites] J Psychiatr Res. 2012 Feb;46(2):205-11 [21944429.001]
  • [Cites] Schizophr Res. 2012 Aug;139(1-3):73-7 [22627122.001]
  • [Cites] Annu Rev Psychol. 2002;53:109-32 [11752481.001]
  • (PMID = 24529609.001).
  • [ISSN] 1573-2509
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K23 MH086755; United States / NIMH NIH HHS / MH / K23MH086755
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS562112; NLM/ PMC3962084
  • [Keywords] NOTNLM ; Intrinsic motivation / Motivation / Psychosocial rehabilitation / Quality of life scale / Schizophrenia
  •  go-up   go-down


5. Seronello S, Ito C, Wakita T, Choi J: Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem; 2010 Jan 8;285(2):845-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+.
  • Ethanol has been suggested to elevate HCV titer in patients and to increase HCV RNA in replicon cells, suggesting that HCV replication is increased in the presence and absence of the complete viral replication cycle, but the mechanisms remain unclear.
  • In this study, we use Huh7 human hepatoma cells that naturally express comparable levels of CYP2E1 as human liver to demonstrate that ethanol, at subtoxic and physiologically relevant concentrations, enhances complete HCV replication.
  • The viral RNA genome replication is affected for both genotypes 2a and 1b.
  • Acetaldehyde, a major product of ethanol metabolism, likewise enhances HCV replication at physiological concentrations.
  • The potentiation of HCV replication by ethanol is suppressed by inhibiting CYP2E1 or aldehyde dehydrogenase and requires an elevated NADH/NAD(+) ratio.
  • In addition, acetate, isopropyl alcohol, and concentrations of acetone that occur in diabetics enhance HCV replication with corresponding increases in the NADH/NAD(+).
  • Furthermore, inhibiting the host mevalonate pathway with lovastatin or fluvastatin and fatty acid synthesis with 5-(tetradecyloxy)-2-furoic acid or cerulenin significantly attenuates the enhancement of HCV replication by ethanol, acetaldehyde, acetone, as well as acetate, whereas inhibiting beta-oxidation with beta-mercaptopropionic acid increases HCV replication.
  • Ethanol, acetaldehyde, acetone, and acetate increase the total intracellular cholesterol content, which is attenuated with lovastatin.
  • In contrast, both endogenous and exogenous ROS suppress the replication of HCV genotype 2a, as previously shown with genotype 1b.
  • CONCLUSION: Therefore, lipid metabolism and alteration of cellular NADH/NAD(+) ratio are likely to play a critical role in the potentiation of HCV replication by ethanol rather than oxidative stress.
  • [MeSH-major] Central Nervous System Depressants / pharmacology. Ethanol / pharmacology. Hepacivirus / physiology. Hepatitis C / mortality. NAD / metabolism. Virus Replication / drug effects
  • [MeSH-minor] Acetaldehyde / pharmacology. Acetone / pharmacology. Aldehyde Dehydrogenase / antagonists & inhibitors. Aldehyde Dehydrogenase / metabolism. Anticholesteremic Agents / pharmacology. Cell Line, Tumor. Cholesterol / metabolism. Cytochrome P-450 CYP2E1 / metabolism. Genome, Viral / physiology. Humans. Lipid Metabolism / drug effects. RNA, Viral / metabolism. Reactive Oxygen Species / metabolism. Solvents / pharmacology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETONE .
  • Hazardous Substances Data Bank. ACETALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2005 Aug 18;436(7053):939-45 [16107833.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1697-703 [15947244.001]
  • [Cites] J Clin Microbiol. 2005 Nov;43(11):5679-84 [16272504.001]
  • [Cites] Virol J. 2005;2:89 [16324217.001]
  • [Cites] Biochem Cell Biol. 2006 Feb;84(1):67-79 [16462891.001]
  • [Cites] Transl Res. 2006 Aug;148(2):79-86 [16890148.001]
  • [Cites] Free Radic Biol Med. 2006 Nov 1;41(9):1488-98 [17023276.001]
  • [Cites] Nat Rev Microbiol. 2007 Jun;5(6):453-63 [17487147.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Jun;51(6):2016-27 [17420205.001]
  • [Cites] Free Radic Biol Med. 2007 Sep 15;43(6):869-82 [17697932.001]
  • [Cites] J Viral Hepat. 2007 Sep;14(9):608-17 [17697012.001]
  • [Cites] PLoS Pathog. 2007 Aug 31;3(8):e108 [17784784.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18666-70 [18003907.001]
  • [Cites] Hepatology. 2008 Jun;47(6):2127-33 [18446789.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1383-9 [18410471.001]
  • [Cites] J Infect Dis. 2008 Dec 15;198(12):1766-75 [18956976.001]
  • [Cites] J Virol. 2009 Mar;83(5):2338-48 [19109388.001]
  • [Cites] Hepatology. 2009 Sep;50(3):678-88 [19492433.001]
  • [Cites] Med Hypotheses. 1999 Sep;53(3):236-42 [10580530.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):152-62 [10611164.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Apr;24(4 Suppl):106S-111S [10803791.001]
  • [Cites] Science. 2000 Dec 8;290(5498):1972-4 [11110665.001]
  • [Cites] Hepatology. 2002 May;35(5):1196-204 [11981770.001]
  • [Cites] J Virol. 2002 Dec;76(24):13001-14 [12438626.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):649-62 [12828960.001]
  • [Cites] Hepatology. 2003 Jul;38(1):57-65 [12829987.001]
  • [Cites] Methods Mol Biol. 1998;107:147-52 [14577224.001]
  • [Cites] Hepatology. 2004 Jan;39(1):81-9 [14752826.001]
  • [Cites] Alcohol Clin Exp Res. 1989 Oct;13(5):601-4 [2688456.001]
  • [Cites] Alcohol Alcohol Suppl. 1991;1:291-6 [1669007.001]
  • [Cites] J Infect Dis. 1994 Jun;169(6):1219-25 [8195599.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23235-8 [7559472.001]
  • [Cites] J Viral Hepat. 1996 May;3(3):143-8 [8871873.001]
  • [Cites] J Hepatol. 1996 Dec;25(6):821-6 [9007708.001]
  • [Cites] Alcohol. 1997 Mar-Apr;14(2):111-5 [9085710.001]
  • [Cites] J Clin Microbiol. 1997 Dec;35(12):3156-62 [9399512.001]
  • [Cites] Alcohol. 2004 Aug;34(1):9-19 [15670660.001]
  • [Cites] Nat Med. 2005 Jul;11(7):791-6 [15951748.001]
  • [Cites] Intervirology. 2006;49(1-2):18-22 [16166784.001]
  • (PMID = 19910460.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Central Nervous System Depressants; 0 / RNA, Viral; 0 / Reactive Oxygen Species; 0 / Solvents; 0U46U6E8UK / NAD; 1364PS73AF / Acetone; 3K9958V90M / Ethanol; 97C5T2UQ7J / Cholesterol; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.2.1.3 / Aldehyde Dehydrogenase; GO1N1ZPR3B / Acetaldehyde
  • [Other-IDs] NLM/ PMC2801286
  •  go-up   go-down


6. Choi J, Park JW, Chung J, Min BG: An intelligent remote monitoring system for artificial heart. IEEE Trans Inf Technol Biomed; 2005 Dec;9(4):564-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intelligent remote monitoring system for artificial heart.
  • A web-based database system for intelligent remote monitoring of an artificial heart has been developed.
  • It is important for patients with an artificial heart implant to be discharged from the hospital after an appropriate stabilization period for better recovery and quality of life.
  • Reliable continuous remote monitoring systems for these patients with life support devices are gaining practical meaning.
  • The authors have developed a remote monitoring system for this purpose that consists of a portable/desktop monitoring terminal, a database for continuous recording of patient and device status, a web-based data access system with which clinicians can access real-time patient and device status data and past history data, and an intelligent diagnosis algorithm module that noninvasively estimates blood pump output and makes automatic classification of the device status.
  • The system has been tested with data generation emulators installed on remote sites for simulation study, and in two cases of animal experiments conducted at remote facilities.
  • The system showed acceptable functionality and reliability.
  • The intelligence algorithm also showed acceptable practicality in an application to animal experiment data.
  • [MeSH-major] Decision Support Systems, Clinical. Diagnosis, Computer-Assisted / methods. Equipment Failure Analysis / methods. Expert Systems. Heart, Artificial. Telemedicine / methods. Therapy, Computer-Assisted / methods
  • [MeSH-minor] Humans. Internet. Monitoring, Physiologic / methods. Online Systems. User-Computer Interface

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16379373.001).
  • [ISSN] 1089-7771
  • [Journal-full-title] IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Inf Technol Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Choi J, Knudsen LE, Mizrak S, Joas A: Identification of exposure to environmental chemicals in children and older adults using human biomonitoring data sorted by age: Results from a literature review. Int J Hyg Environ Health; 2017 Mar;220(2 Pt A):282-298
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of exposure to environmental chemicals in children and older adults using human biomonitoring data sorted by age: Results from a literature review.
  • Human biomonitoring (HBM) provides the tools for exposure assessment by direct measurements of biological specimens such as blood and urine.
  • HBM can identify new chemical exposures, trends and changes in exposure, establish distribution of exposure among the general population, and identify vulnerable groups and populations with distinct exposures such as children and older adults.
  • The objective of this review is to demonstrate the use of HBM to identify environmental chemicals that might be of concern for children or older adults due to higher body burden.
  • To do so, an extensive literature search was performed, and using a set of defined criteria, ten large-scale, cross-sectional national HBM programs were selected for data review and evaluation.
  • A comparative analysis of the age-stratified data from these programs and other relevant HBM studies indicated twelve chemicals/classes of chemicals with potentially higher body burden in children or older adults.
  • Children appear to have higher body burden of bisphenol A (BPA), some phytoestrogens, perchlorate, and some metabolites of polycyclic aromatic hydrocarbons and benzene.
  • On the other hand, older adults appear to have higher body burden of heavy metals and organochlorine pesticides.
  • For perfluoroalkyl substances, polybrominated diphenyl ethers, parabens, and phthalates, both children and older adults have higher body burden depending on the specific biomarkers analyzed, and this might be due to the exposure period and/or sources from different countries.
  • Published data from the DEMOCOPHES project (a pilot study to harmonize HBM efforts across Europe) also showed elevated exposures to BPA and some phthalate metabolites in children across several European countries.
  • In summary, age-stratified HBM data can provide useful knowledge of identifying environmental chemicals that might be of concern for children and older adults, which, combined with additional efforts to identify potential sources of exposure, could assist policy makers in prioritizing their actions in order to reduce chemical exposure and potential risks of adverse health effects.
  • [MeSH-major] Environmental Monitoring / statistics & numerical data. Environmental Pollutants / analysis
  • [MeSH-minor] Adult. Age Factors. Child. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier GmbH. All rights reserved.
  • (PMID = 28159478.001).
  • [ISSN] 1618-131X
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Environmental Pollutants
  • [Keywords] NOTNLM ; Age / Children / Human biomonitoring / Older adults / Vulnerable groups
  •  go-up   go-down


8. Seol JW, Yi W, Choi J, Lee KS: Causality patterns and machine learning for the extraction of problem-action relations in discharge summaries. Int J Med Inform; 2017 Feb;98:1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causality patterns and machine learning for the extraction of problem-action relations in discharge summaries.
  • Clinical narrative text includes information related to a patient's medical history such as chronological progression of medical problems and clinical treatments.
  • A chronological view of a patient's history makes clinical audits easier and improves quality of care.
  • In this paper, we propose a clinical Problem-Action relation extraction method, based on clinical semantic units and event causality patterns, to present a chronological view of a patient's problem and a doctor's action.
  • Based on our observation that a clinical text describes a patient's medical problems and a doctor's treatments in chronological order, a clinical semantic unit is defined as a problem and/or an action relation.
  • Since a clinical event is a basic unit of the problem and action relation, events are extracted from narrative texts, based on the external knowledge resources context features of the conditional random fields.
  • A clinical semantic unit is extracted from each sentence based on time expressions and context structures of events.
  • Then, a clinical semantic unit is classified into a problem and/or action relation based on the event causality patterns of the support vector machines.
  • Experimental results on Korean discharge summaries show 78.8% performance in the F1-measure.
  • This result shows that the proposed method is effectively classifies clinical Problem-Action relations.
  • [MeSH-major] Decision Support Systems, Clinical. Electronic Health Records / utilization. Machine Learning. Natural Language Processing. Patient Discharge / standards. Semantics
  • [MeSH-minor] Humans. Narration. Pattern Recognition, Automated. Support Vector Machine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 28034407.001).
  • [ISSN] 1872-8243
  • [Journal-full-title] International journal of medical informatics
  • [ISO-abbreviation] Int J Med Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; Causality pattern / Clinical semantic unit / Machine learning / Problem-Action relation / Relation extraction
  •  go-up   go-down


9. Choi J, Kim TH, Choi TY, Lee MS: Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS One; 2013;8(4):e59978
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ginseng for health care: a systematic review of randomized controlled trials in Korean literature.
  • OBJECTIVE: This systematic review was performed to summarise randomised clinical trials (RCTs) assessing the efficacy and safety of ginseng in the Korean literature.
  • METHOD: The study involved systematic searches conducted in eight Korean Medical databases.
  • The methodological quality of all of the included studies was assessed using the Cochrane Risk of Bias tool.
  • We included all RCTs on any type of ginseng compared to placebo, active treatment or no treatment in healthy individuals or patients regardless of conditions.
  • RESULTS: In total, 1415 potentially relevant studies were identified, and 30 randomised clinical trials were included.
  • Nine RCTs assessed the effects of ginseng on exercise capacity, cognitive performance, somatic symptoms, quality of life, and sleeping in healthy persons.
  • Six RCTs tested ginseng compared with placebo for erectile dysfunction, while another four studies evaluated the effects of ginseng against no treatment for gastric and colon cancer.
  • Two RCTs compared the effect of red ginseng on diabetes mellitus with no treatment or placebo, and the other nine RCTs assessed the effects of ginseng compared with placebo or no treatment on various conditions.
  • The methodological caveats of the included trials make their contribution to the current clinical evidence of ginseng somewhat limited.
  • However, the 20 newly added trials (66.7% of the 30 trials) may provide useful information for future trials.
  • Ginseng appears to be generally safe, and no serious adverse effects have been reported.
  • CONCLUSIONS: The clinical effects of ginseng have been tested in a wide range of conditions in Korea.
  • Although the quality of RCTs published in the Korean literature was generally poor, this review is useful for researchers to access studies that were originally published in languages that they would otherwise be unable to read and due to the paucity of evidence on this subject.
  • [MeSH-major] Diabetes Mellitus / drug therapy. Erectile Dysfunction / drug therapy. Gastrointestinal Neoplasms / drug therapy. Panax / chemistry. Phytotherapy. Plant Preparations / therapeutic use. Sleep Wake Disorders / drug therapy
  • [MeSH-minor] Asian Continental Ancestry Group. Databases, Factual. Female. Humans. Male. Medicine, Korean Traditional. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 1999 Oct;55(8):567-75 [10541774.001]
  • [Cites] Phytother Res. 2013 Jul;27(7):949-65 [22969004.001]
  • [Cites] Ann Pharmacother. 2006 Jan;40(1):83-95 [16332943.001]
  • [Cites] J Med Assoc Thai. 2007 Jun;90(6):1172-9 [17624213.001]
  • [Cites] Can J Clin Pharmacol. 2008 Winter;15(1):e87-94 [18204104.001]
  • [Cites] Adv Food Nutr Res. 2009;55:1-99 [18772102.001]
  • [Cites] Br J Clin Pharmacol. 2008 Oct;66(4):444-50 [18754850.001]
  • [Cites] J Alzheimers Dis. 2009;18(2):339-44 [19584437.001]
  • [Cites] Respir Med. 2011 Feb;105(2):165-76 [21146973.001]
  • [Cites] J Altern Complement Med. 2011 Jan;17(1):45-9 [21235416.001]
  • [Cites] J Acupunct Meridian Stud. 2011 Jun;4(2):85-97 [21704950.001]
  • [Cites] Chin J Integr Med. 2011 Dec;17(12):937-44 [22139546.001]
  • [Cites] Complement Ther Med. 2012 Jun;20(3):155-66 [22500665.001]
  • [Cites] J Altern Complement Med. 2012 Nov;18(11):1061-9 [22909282.001]
  • [Cites] Altern Med Rev. 2004 Sep;9(3):259-74 [15387718.001]
  • (PMID = 23560064.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Preparations
  • [Other-IDs] NLM/ PMC3613407
  •  go-up   go-down


10. Gang J, Choi J, Lee JH, Nham SU: Identification of critical residues for plasminogen binding by the alphaX I-domain of the beta2 integrin, alphaXbeta2. Mol Cells; 2007 Oct 31;24(2):240-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of critical residues for plasminogen binding by the alphaX I-domain of the beta2 integrin, alphaXbeta2.
  • The beta2 integrins on leukocytes play important roles in cell adhesion, migration and phagocytosis.
  • One of the beta2 integrins, alphaXbeta2 (CD11c/CD18), is known to bind ligands such as fibrinogen, Thy-1 and iC3b, but its function is not well characterized.
  • To understand its biological roles, we attempted to identify novel ligands.
  • The functional moiety of alphaXbeta2, the alphaX I-domain, was found to bind plasminogen, the zymogen of plasmin, with moderate affinity (1.92 X 10-(6) M) in the presence of Mg(2+) or Mn(2+).
  • The betaD-alpha5 loop of the alphaX I-domain proved to be responsible for binding, and lysine residues (Lys(242), Lys(243)) in the loop were the most important for recognizing plasminogen.
  • An excess amount of the lysine analog, 6-aminohexanoic acid, inhibited alphaX I-domain binding to plasminogen, indicating that binding is lysine-dependent.
  • The results of this study indicate that leukocytes regulate plasminogen activation, and consequently plasmin activities, through an interaction with alphaXbeta2 integrin.
  • [MeSH-major] Integrin alphaXbeta2 / chemistry. Integrin alphaXbeta2 / metabolism. Plasminogen / metabolism
  • [MeSH-minor] Amino Acids / chemistry. Amino Acids / metabolism. Binding Sites. Crystallography, X-Ray. Humans. Kinetics. Lysine / analogs & derivatives. Mutant Proteins / metabolism. Peptides / metabolism. Protein Binding. Protein Structure, Tertiary. Recombinant Fusion Proteins / metabolism. Structure-Activity Relationship. Surface Plasmon Resonance

  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978577.001).
  • [ISSN] 1016-8478
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Integrin alphaXbeta2; 0 / Mutant Proteins; 0 / Peptides; 0 / Recombinant Fusion Proteins; 9001-91-6 / Plasminogen; K3Z4F929H6 / Lysine
  •  go-up   go-down






Advertisement